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PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leu-
kemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary 
analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant im-
provements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update 
results at a median follow-up of 11.4 years.
PATIENTS AND METHODS Patients age 65 years or older with early breast cancer were randomly assigned 
to either standard adjuvant chemotherapy (physician’s choice of either cyclophosphamide, methotrex-
ate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian de-
sign was used to determine sample size and test noninferiority of capecitabine. The primary end point 
was RFS.
RESULTS The design stopped accrual with 633 patients at its first sample size assessment. RFS remains 
significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with 
standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 
0.80; P = .03); breast cancer–specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and 
overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard 
chemotherapy remains superior to capecitabine among hormone receptor–negative patients (HR, 0.66; P = 
.02), but not among hormone receptor–positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have 
died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown 
causes). Second nonbreast cancers occurred in 14.1% of patients.
CONCLUSION With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus cape-
citabine, especially in patients with hormone receptor–negative disease. Competing risks in this older population 
dilute overall survival benefits.
J Clin Oncol 37:2338-2348. 
INTRODUCTION
Increasing age is the major risk factor for breast
cancer.1 The average age at diagnosis of breast
cancer in the United States is now 62 years, and the
majority of women who die of breast cancer are
age 65 years and older.1 Despite major advances
over the past 30 years in prolonging breast cancer
survival for women of all ages, there is some evi-
dence that breast cancer–specific survival (BCSS)
remains lowest in older women.2 The reasons
for this are unclear, but most compelling is the
underuse of adjuvant systemic therapy in these
older patients.3,4
In 2009, the Cancer and Leukemia Group B (now part
of the Alliance for Clinical Trials in Oncology) reported
initial results of a randomized trial specifically designed
for women with early-stage breast cancer age 65 years
and older that compared standard chemotherapy
(physician’s choice of cyclophosphamide, metho-
trexate, and fluorouracil [CMF] or doxorubicin and
cyclophosphamide [AC]) with capecitabine.5 Previous
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similar outcomes in the adjuvant setting.6,7 In metastatic
breast cancer, capecitabine had been shown to be asso-
ciated with response rates approximating 30%8 and, in one
randomized phase II trial, showed similar activity to CMF.9
Our trial was designed to show recurrence-free survival
(RFS) noninferiority of capecitabine and used a novel
Bayesian adaptive design. After enrolling 600 patients, the
probability that with longer follow-up capecitabine was
highly likely to be noninferior met a prespecified cutoff
value, and enrollment was discontinued. The final sample
size was 633 patients. At the time of the earlier publication,
themedian follow-up time was 2.4 years, and themaximum
follow-up time was 5.6 years. The estimated 3-year RFS
rate was 85% in the standard chemotherapy group com-
pared with 68% in the capecitabine group, and the overall
survival (OS) rates were 91% and 86%, respectively; both
differences were statistically significant. Because of the
limited follow-up in our earlier report, we now assess the
risks and benefits of treatment after a median follow-up
time of 11.4 years. In addition, we calculate BCSS and




Eligibility criteria required that patients be age 65 years or
older with operable, histologically confirmed adenocarci-
noma of the breast. Performance status had to be 0 to 2
(National Cancer Institute criteria). Patients were ineligible
if they had another active malignancy with a risk of relapse
of greater than 30%. Complete details on eligibility criteria
have been previously published5 and can also be found in
the Data Supplement.
Random Assignment and Study Treatment
All patients were required to give written informed consent
meeting all state, federal, and institutional guidelines. Eli-
gible patients were randomly assigned in a one-to-one ratio
to either standard chemotherapy or capecitabine. Standard
chemotherapy consisted of either CMF (cyclophosphamide
100 mg/m2 orally on days 1 to 14 and methotrexate
40 mg/m2 and fluorouracil 600 mg/m2 on days 1 and 8
intravenously; cycles were repeated every 28 days for six
cycles) or AC (doxorubicin 60 mg/m2 and cyclophospha-
mide 600 mg/m2 intravenously on day 1; cycles were re-
peated every 21 days for four cycles). For patients randomly
assigned to standard chemotherapy, the physician and
patient selected either CMF or AC. Patients randomly
assigned to capecitabine received a dosage of 2,000 mg/m2
per day for 14 consecutive days every 3 weeks for six
cycles. Doses were based on actual body weight, and there
were no dose limits. For all regimens, toxicity assessment
and dose modifications were based on standard National
Cancer Institute Common Terminology Criteria for Adverse
Events criteria (version 3.0)10 and were clearly defined in
the protocol.
Statistical Design
The study was designed as a noninferiority trial comparing
capecitabine with standard chemotherapy and used
a unique adaptive Bayesian design.11 The primary end
point was RFS, as defined by Standardized Definitions for
Efficacy End Points in Adjuvant Breast Cancer Trials cri-
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metastasis, or death as a result of any cause. The trial
assumed a 5-year RFS of 60% for standard chemother-
apy, and capecitabine was considered to be noninferior if
its 5-year RFS was 53% or higher. The planned sample
size was 600 to 1,800 patients. Interim monitoring was
devised for both futility and noninferiority on the basis
of Bayesian predictive probabilities assuming non-
informative prior distributions. Interim analyses were
scheduled to occur when 600, 900, 1,200, and 1,500
patients had been enrolled; randomization was not
adaptive. Further details on our selection of trial sample
sizes have been previously published.5 OS was a sec-
ondary end point.
In this report, we also analyzed BCSS, defined as time from
registration until death as a result of breast cancer. This end
point was not prespecified in the protocol, and these an-
alyses are exploratory because the cause of death was not
completely ascertained in a large number of patients. For
BCSS, deaths as a result of causes other than breast cancer
or from unknown causes were censored at the time death
occurred. All efficacy analyses were based on the intent-to-
treat principle and included all patients who were randomly
assigned. The reverse Kaplan-Meier method was used to
estimate the extent of clinical follow-up maturity.13 Kaplan-
Meier curves were used to estimate RFS, OS, and BCSS.14
Cox proportional hazards models were used to compare
TABLE 1. Baseline Patient Characteristics
Characteristic






65-69 110 (34) 108 (35)
70-79 204 (63) 185 (60)
$ 80 12 (4) 14 (5)
Performance status
0 or 1 (fully active or
minimal symptoms)
317 (97) 295 (96)
2 (symptoms, but active
. 50% of the time)
9 (3) 12 (4)
Race
White 277 (85) 261 (85)
Other 46 (14) 37 (12)
Missing data 3 (1) 9 (3)
Tumor size, cm
# 2 159 (49) 120 (39)
. 2 - # 5 147 (45) 169 (55)
. 5 18 (6) 17 (6)
Missing data 2 (, 1) 0 (0)
No. of positive lymph nodes
0 90 (28) 95 (31)
1-3 180 (55) 157 (51)
4-9 39 (12) 42 (14)
$ 10 13 (4) 9 (3)
Missing data 4 (1) 4 (1)
Tumor grade
Low 46 (14) 36 (12)
Intermediate 124 (38) 132 (43)
High 131 (40) 127 (41)
Missing data 25 (8) 12 (4)
Hormone receptor status
Negative 106 (33) 97 (32)
Positive 219 (67) 210 (68)
Missing data 1 (, 1) 0 (0)
ER and PR status
ER negative, PR negative 106 (33) 97 (32)
ER positive, PR negative 40 (12) 54 (18)
ER negative, PR positive 6 (2) 5 (2)
ER positive, PR positive 172 (53) 150 (49)
Missing data 2 (1) 1 (, 1)
HER2 status
Positive 39 (12) 37 (12)
Negative 275 (84) 254 (83)
Unknown 12 (4) 16 (5)
(continued in next column)
TABLE 1. Baseline Patient Characteristics (continued)
Characteristic





ER, PR, and HER2 status
ER or PR positive, HER2
negative
196 (60) 177 (58)
ER, PR, and HER2 negative
(triple-negative)




152 (47) 136 (44)
Mastectomy 172 (53) 169 (55)
Missing data 2 ( , 1) 2 (, 1)
Axillary evaluation
Sentinel node biopsy only 64 (20) 67 (22)
Axillary dissection only 115 (35) 100 (33)
Both sentinel node biopsy and
axillary dissection
142 (44) 136 (44)
Neither sentinel node biopsy nor
axillary dissection
4 (1) 3 (, 1)
Missing data 1 (, 1) 1 (, 1)
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF,
cyclophosphamide, methotrexate, and fluorouracil; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; PR,
progesterone receptor.
treatment effects between arms, adjusting for tumor size,
lymph node status, hormone receptor status, age, and race.
These long-term outcome comparisons were not pre-
planned in the original protocol, which used a Bayesian
adaptive design. The P values presented here are de-
scriptive only. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC). Data collection and
statistical analyses were conducted by the Alliance Sta-
tistics and Data Center. Data quality was ensured by review
of data by the Alliance Statistics and Data Center and by the
study chairperson following Alliance policies.
RESULTS
Study Conduct
This long-term outcome analysis is based on data available
as of December 31, 2017. The trial opened for accrual on
September 15, 2001, and was closed on December 29,
2006, after 633 patients had been entered. Six hundred
patients were accrued as of November 2006, and the first
planned analysis concluded that the probability that
capecitabine would be noninferior to standard chemo-
therapy met our preplanned criteria for futility. The median
follow-up time for RFS was 11.4 years (95%CI, 11.2 to 11.6
years).
Patient Characteristics
Three hundred twenty-six patients were randomly assigned
to the standard treatment arm, and 307 patients were
assigned to the capecitabine arm (Fig 1). Nine patients in
the standard treatment arm never received treatment,
leaving 317 patients who were treated (184 patients with
AC and 133 patients with CMF). Patient characteristics are
listed in Table 1. Approximately two thirds of the patients
were age 70 years and older, and approximately 5% were
age 80 years and older. Almost all patients had excellent
performance status (ambulatory and without any symp-
toms), and the majority of patients were white (85%). More
than half of patients had tumors larger than 2 cm, andmore
than two thirds of patients had positive lymph nodes. Two
thirds of patients were hormone receptor positive, and
approximately 12% were human epidermal growth factor
receptor 2 positive.
RFS, OS, and BCSS
For the entire cohort, the 10-year RFS, OS, and BCSS rates
were 52.7% (95% CI, 48.8% to 57%), 59.2% (95% CI,
55.3% to 63.4%), and 85.4% (95% CI, 82.4% to 88.5%),
respectively (Appendix Table A1 and Appendix Figs A1 to
A3, online only). Table 2 compares RFS events and OS
events between our initial report and this update. Ap-
proximately half of all patients now have an RFS event, and
approximately 44%have died. Estimated 10-year RFS rates
are 55.7% (95% CI, 50.2% to 61.7) and 49.7% (95% CI,
44.1% to 56%) for standard chemotherapy and capeci-
tabine, respectively (Fig 2). The Kaplan-Meier curves
for RFS and OS seem to cross toward the later period of
follow-up (Fig 2; P = .05 and P = .02 for the test of non-
proportionality for RFS and OS, respectively). The non-
proportionality for end points that involve non–breast
cancer–specific death is not surprising given other com-
peting causes of death in this elderly population. In the
TABLE 2. Recurrence-Free and Overall Survival Events
Event or Patient Status
No. of Patients (%)
2009* 2018
CMF or AC (n = 326) Capecitabine (n = 307) CMF or AC (n = 326) Capecitabine (n = 307)
Recurrence-free survival
Alive without relapse 291 (89.3) 247 (80.5) 171 (52) 146 (48)
Total events 35 (10.7) 60 (19.5) 155 (48) 161 (52)
Local recurrence only 5 (1.5) 19 (6.2) 17 (5) 28 (9)
Distant metastases 15 (4.6) 24 (7.8) 41 (13) 44 (14)
Died without relapse 15 (4.6) 17 (5.5) 97 (30) 89 (29)
Overall survival
Alive 302 (93) 269 (88) 187 (57) 168 (55)
Total deaths 24 (7.4) 38 (12.4) 139 (43) 139 (45)
Cause of death
Breast cancer 8 (2.5) 18 (5.9) 34 (10) 49 (16)
Breast cancer treatment 0 (0) 2 (0.7) 0 2 (0.7)
Cause other than breast cancer 12 (3.3) 14 (4.6) 56 (17) 48 (16)
Unknown 4 (0.8) 4 (1.3) 49 (15) 40 (13)
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil.
*Data from initial publication.5
multivariable analysis (Table 3), RFS, BCSS, and OS fa-
vored patients treated with standard therapy (RFS: hazard
ratio [HR], 0.80; 95% CI, 0.62 to 0.98; P = .03; BCSS: HR,
0.62; 95% CI, 0.39 to 0.97; P = .03; OS: HR, 0.84; 95% CI,
0.66 to 1.07; P = .16). As expected and similar to our earlier
report, larger tumor size, a greater number of positive
nodes, and negative hormone receptor status were asso-
ciated with significantly poorer outcomes, whereas race
was not. Of interest, multivariable analysis also found that
patients age 70 years and older had significantly poorer
prognosis compared with those age 65 to 69 years. Be-
cause death from any cause is considered an RFS event
and because increasing age is associated with shorter life
expectancy, these findings are not unexpected. Of note,
almost two thirds of RFS events were a result of deaths
without relapse and were similar in both treatment groups.
At the time of this update, 43.9% of patients have died
(13.1% from breast cancer, 16.4% from non–breast
cancer causes, and 14.1% from unknown causes). Second
new cancers occurred in 14.7% of patients (16.9% of
patients who received standard therapy v 12.4% of patients
who received capecitabine). Breast cancer accounted for
10%and 16%of all deaths in patients treated with standard
therapy versus capecitabine, respectively (P = .045),
whereas deaths not attributable to breast cancer were
reported for 17% and 16% of patients treated with standard
therapy versus capecitabine, respectively. In approximately
14% of all patients, the cause of death was unknown. Only
two deaths, both in the capecitabine arm, were definitely
related to treatment.
Before the development of this trial, the potential benefits of
chemotherapy for patients with hormone receptor–positive
versus hormone receptor–negative tumors were not well
defined. In an unplanned subset analysis done for our initial
report, a statistically significant interaction between treat-
ment and receptor status was noted for both RFS and OS,
and the benefits of standard chemotherapy were confined
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FIG 2. Kaplan-Meier plots for
(A) recurrence-free survival,
(B) overall survival, and (C)
breast cancer–specific survival
by treatment arm. AC, doxoru-
bicin and cyclophosphamide;
CMF, cyclophosphamide, meth-
otrexate, and fluorouracil; HR,
hazard ratio.
follow-up analysis, RFS remains significantly better for
patients with hormone receptor–negative tumors treated
with standard chemotherapy compared with capecitabine
(HR, 0.66; 95% CI, 0.46 to 0.95; P = .02), but this benefit
was not observed among patients with hormone recep-
tor–positive tumors (HR, 0.89; 95% CI, 0.68 to 1.18; P =
.43; Fig 3). The interaction test between treatment and
hormone receptor status for RFS yielded a nominal P = .15,
possibly as a result of the limited statistical power available
for interaction tests.15 For OS and BCSS, the treatment
difference did not reach statistical significance in either
hormone receptor subgroup, likely because of the limited
power in these subgroup analyses. Nevertheless, there was
a visual trend toward greater magnitude of efficacy with
standard chemotherapy among patients with hormone
receptor–negative tumors.
In this update, we specifically analyzed data from the 154
patients with triple-negative breast cancer in an exploratory
analysis (Appendix Table A2 to A4 and Appendix Figs A4
to A6, online only). Similar to hormone receptor–negative
patients, RFS was significantly improved for patients with
triple-negative breast cancer treated with standard che-
motherapy (HR, 0.61; 95% CI, 0.39 to 0.95; P = .03).
However, no significant difference was noted between the
two arms for OS (HR, 0.71; 95% CI, 0.45 to 1.14; P = .15)
or BCSS (HR, 0.56; 95% CI, 0.25 to 1.25; P = .16).
Toxicity and Second Cancers
Toxicity data have been previously published.5 Two patients
on capecitabine had drug-related deaths. With longer
follow-up, 89 (14.1%) of 633 patients have developed new
second primary cancers, 55 patients (16.9%) in the
standard therapy group and 38 patients (12.4%) in the
capecitabine group (P = .12; Table 4). At this time, death
attributed to congestive heart failure (six patients) or car-
diomyopathy (three patients) has been noted for seven
patients treated with standard therapy (AC, n = 5; CMF, n =
2) and two patients treated with capecitabine (one patient
with congestive heart failure and one with cardiomyopathy).
Myelodysplasia was reported in two patients (one patient
treated with capecitabine and one treated with standard
therapy). Acute myelogenous leukemia was reported in one
patient receiving standard therapy.
DISCUSSION
Initial results of this trial showed that standard chemo-
therapy with CMF or AC resulted in superior RFS compared
with capecitabine in older women with early-stage breast
cancer. Now with longer follow-up, standard chemotherapy
TABLE 3. Multivariable Analysis of Treatment Effect Adjusting for Baseline Characteristics for All ITT Patients
Variable
Recurrence-Free Survival Overall Survival Breast Cancer–Specific Survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Treatment
Capecitabine 1 (Ref) .0312 1 (Ref) .1629 1 (Ref) .0348
CMF or AC 0.80 (0.62 to 0.98) 0.84 (0.66 to 1.07) 0.62 (0.39 to 0.97)
Age group, years
65-69 1 (Ref) , .001 1 (Ref) , .001 1 (Ref) .0359
$ 70 1.57 (1.21 to 2.04) 1.85 (1.39 to 2.48) 1.82 (1.04 to 3.18)
Race
White 1 (Ref) .6112 1 (Ref) .7344 1 (Ref) .664
Other 1.09 (0.79 to 1.50) 0.94 (0.66 to 1.34) 1.14 (0.63 to 2.08)
Tumor size, cm
# 2 1 (Ref) .004 1 (Ref) , .001 1 (Ref) .0011
. 2 1.41 (1.12 to 1.79) 1.56 (1.21 to 2.01) 2.39 (1.41 to 4.03)
No. of positive lymph nodes
0 1 (Ref) , .001 1 (Ref) , .001 1 (Ref) , .001
1-3 1.76 (1.31 to 2.36) 1.73 (1.27 to 2.38) 1.95 (1.02 to 3.72)
$ 4 2.18 (1.54 to 3.08) 2.35 (1.63 to 3.39) 5.02 (2.63 to 9.60)
Hormone receptor status
Positive 1 (Ref) , .001 1 (Ref) , .001 1 (Ref) .003
Negative 1.69 (1.32 to 2.16) 1.73 (1.33 to 2.25) 2.02 (1.27 to 3.20)
NOTE. Patients with any missing covariates were excluded from the analysis.
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil; HR, hazard ratio; ITT,
intent-to-treat; Ref, reference.
remains significantly superior to capecitabine for RFS
and BCSS but not OS. Similar to our earlier report, the
major benefit of standard chemotherapy was seen in RFS
among patients with hormone receptor–negative disease.
A difference in the rate of metastatic disease among
treatment groups is no longer apparent, with most of the
breast cancer relapse differences being a result of local
regional recurrence. The reason for the lack of a signifi-
cant survival difference after longer follow-up is likely
a result of the large number of deaths from non–breast
cancer causes in this older population, diluting the
benefits of adjuvant treatment.16 Now with 11.4 years of
follow-up, the majority of the 278 deaths in this trial were
a result of causes other than breast cancer (104 deaths;
37.4%) or unknown causes (89 deaths; 32.0%). Only 85
of the total deaths (30.6%) were caused by breast cancer
(including two treatment-related deaths on capecita-
bine). Although it is uncertain how many of the deaths
from unknown causes were a result of breast cancer,
these data underscore the importance of competing
causes of mortality in this older population. This is es-
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FIG 3. Kaplan-Meier plots for recurrence-free survival in patients with (A) hormone receptor–positive and (B) hormone receptor–negative tumors,
overall survival in patients with (C) hormone receptor–positive and (D) hormone receptor–negative tumors, and breast cancer–specific survival in
patients with (E) hormone receptor–positive and (F) hormone receptor–negative tumors by treatment arm. AC, doxorubicin and cyclophosphamide;
CMF, cyclophosphamide, methotrexate, and fluorouracil; HR, hazard ratio.
trials, older patients are likely to be healthier than the older
population at large.
As reported previously, toxicity was seen in the majority of
patients. Only 62% of patients completed all six planned
cycles of CMF, but 80% completed six planned cycles
of capecitabine, and 92% completed four cycles of AC
therapy. With further follow-up, death attributed to con-
gestive heart failure or cardiomyopathy has been noted for
seven patients treated with standard therapy (AC, n = 5;
CMF, n = 2) and two treated with capecitabine. Myelo-
dysplasia and acute myelogenous leukemia were seen in
only three patients.
This trial remains among the few focused on the role of
adjuvant chemotherapy in older women with breast cancer.
Since the publication of our initial results in 2009, few
additional randomized trials focused on this population
have been performed. Two trials compared capecitabine
with a nonchemotherapy control group. One randomized
trial compared ibandronate with or without capecitabine in
1,358 older patients with moderate- or high-risk early
breast cancer and showed no benefit for capecitabine 17 A
second case-control study compared 104 older patients
given adjuvant capecitabine with a similar untreated control
group of 147 patients.18 Considering the negative outcome
from our trial and the larger trial by vonMinckwitz et al,17 we
do not believe that capecitabine alone has a role in the
adjuvant treatment of older women with breast cancer.
Clinical trials in older patients remain sparse. A randomized
trial of CMF or weekly docetaxel in 302 patients age 65 to
69 years showed no difference in outcome after a median
follow-up of almost 6 years19 A second trial randomly
assigned 198 nonfrail patients age 65 years and older to
epirubicin and cyclophosphamide followed by CMF versus
six cycles of nanoparticle albumin-bound paclitaxel and
capecitabine.20 There was no difference in survival among
the treatment groups at 2 years of follow-up. Two phase II
trials have focused on specific regimens such as docetaxel
and cyclophosphamide21,22 and liposomal doxorubicin and
taxanes, but convincing outcome data were lacking23
Unfortunately, in a meta-analysis reported in 2012 of
100,000 women in 123 randomized trials, only a small
percentage of patients age 70 years and older were treated,
limiting our knowledge about the benefits of many newer
state-of-the-art regimens in older patients.24 Accrual of
older patients to groundbreaking adjuvant chemotherapy
trials remains a major problem.
We have learned much about adjuvant therapy since the
initial development and publication of our study. First,
many of the patients enrolled in our trial would not currently
be recommended to receive chemotherapy, especially
many node-negative patients in whom genetic-based as-
says would likely suggest no benefit.25,26 In addition, al-
though CMF and AC result in similar outcomes,6,7 the
majority of lower risk patients receiving chemotherapy to-
day are treated with docetaxel and cyclophosphamide,
a combination that is superior to AC (and CMF) and that
showed similar benefits for patients older and younger than
65 years.27 The use of geriatric assessment to help select
older patients for chemotherapy treatment has also proven
to be of great value28 because performance status misses
many areas of vulnerability in older patients29 and geriatric
assessment can inform the choice of interventions in ad-
dition to allowing one to accurately predict life expectancy30
and toxicity.31,32
In addition to commonly defined clinical trial outcomes
including RFS, OS, BCSS, and toxicity, this trial in-
corporated prospectively collected ancillary data (Data
Supplement) on a number of geriatric-related domains.
This has resulted in numerous publications exploring the
effects of the chemotherapy regimens used in our trial on
quality of life,33 adherence to oral chemotherapy,34,35 self-
reported cognitive function,36 lymphedema and musculo-
skeletal events,37 and functional decline.38 Pretreatment
data were also used to assess the effects of comorbidity,39
social support,40 renal function,41 patient preferences to
receive chemotherapy,42 and selected covariates43 on
patient outcomes. In addition, we developed a compan-
ion trial (ClinicalTrials.gov identifier: NCT00068328) for
TABLE 4. New Second Primary Cancers
Second Cancer
No. of Patients (%)
CMF or AC (n = 58) Capecitabine (n = 38) Total (N = 96)
Solid tumor 24 (41) 14 (37) 38 (40)
GI 7 (12) 2 (5) 9 (9)
Genitourinary 2 (3) 3 (8) 5 (5)
Gynecologic 6 (10) 2 (5) 8 (8)
Other 7 (12) 7 (18) 14 (15)
Breast 8 (14) 6 (16) 14 (15)
Invasive 5 (9) 3 (8) 8 (8)
DCIS/LCIS 3 (5) 3 (8) 6 (6)
Skin 6 (10) 6 (16) 12 (13)
Blood 9 (16) 5 (13) 14 (15)
Lymphoma 3 (5) 1 (3) 4 (4)
Myeloma 1 (2) 2 (5) 2 (2)
Myelodysplasia 2 (3) 1 (3) 3 (3)
AML 2 (3) 0 (0) 2 (2)
CLL 0 (0) 1 (3) 1 (1)
CML 1 (2) 0 (0) 1 (1)
Unknown 11 (19) 7 (18) 18 (19)
NOTE. Among the 89 patients who developed a second cancer, there were 96
cancer occurrences in total. Six patients had multiple secondary cancer events, all
on the cyclophosphamide, methotrexate, and fluorouracil (CMF) or doxorubicin
and cyclophosphamide (AC) arm.
Abbreviations: AML, acute myelogenous leukemia; CLL, chronic lymphocytic
leukemia; CML, chronic myelogenous leukemia; DCIS, ductal cancer in situ; LCIS,
lobular cancer in situ.
patients who declined participation in the Cancer and
Leukemia Group B 49907 trial (Alliance) that ran simul-
taneously and that compared treatment and other out-
comes with the treatment groups in our study.44 These
assessments related to quality of life and function and the
need for supportive care during treatment are key to dis-
cussing treatment recommendations with patients. Another
unique aspect of our trial was the use of an adaptive
Bayesian statistical design that allowed us to determine
noninferiority with a smaller sample size while retaining the
robustness of the treatment comparisons. Such adaptive
designs should be considered for future trials designed
specifically for older patients to facilitate accrual. The
majority of patients who die of breast cancer in the United
States are age 65 years and older, and our data and those of
others indicate that chemotherapy can improve outcomes
in this older age group. An online calculator validated in
older patients can also help define the benefits of che-
motherapy in patients with different tumor phenotypes.45
Optimally, we must increase the number of older patients in
cancer clinical trials to have accurate data on outcomes,
especially toxicity, for newer agents. Efforts are being made
to overcome the age bias associated with offering older
patients trial participation,46,47 but trials designed specifi-
cally for older patients and that include serial geriatric
assessments are needed.
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FIG A4. Kaplan-Meier plots for recurrence-free survival in patients
with triple-negative breast cancer. AC, doxorubicin and cyclophos-
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FIG A5. Kaplan-Meier plots for overall survival in patients with triple-
negative breast cancer. AC, doxorubicin and cyclophosphamide; CMF,
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FIG A6. Kaplan-Meier plots for breast cancer–specific survival in
patients with triple-negative breast cancer. AC, doxorubicin and
cyclophosphamide; CMF, cyclophosphamide, methotrexate, and
fluorouracil; HR, hazard ratio.
TABLE A1. RFS, OS, and BCSS Estimates at 5 and 10 Years
Kaplan-Meier Estimates for All ITT Patients Median (years; 95% CI) 5-Year Estimate (%; 95% CI) 10-Year Estimate (%; 95% CI)
RFS 10.7 (9.7 to 12.1) 76.3 (73.0 to 79.7) 52.7 (48.8 to 57.0)
OS 12.2 (11.3 to 13.6) 81.6 (78.6 to 84.7) 59.2 (55.3 to 63.4)
BCSS NA 91.7 (89.5 to 94.0) 85.4 (82.4 to 88.5)
NOTE. Median follow-up times were 11.4 years (95% CI, 11.2 to 11.6 years) for relapse-free survival (RFS), 11.4 years (95% CI, 11.3 to 11.7
years) for overall survival (OS), and 10.5 years (95% CI, 10.0 to 10.8 years) for breast cancer–specific survival (BCSS).
Abbreviations: NA, not available; ITT, intent to treat.
TABLE A2. Characteristics of Patients With Triple-Negative Breast Cancer
Characteristic







Age group, years .10
65-69 14 (18) 25 (33)
70-79 57 (73) 45 (59)
$ 80 7 (9) 6 (8)
Performance score 1.00
0 or 1 (fully active or minimal
symptoms)
75 (96) 73 (96)
2 (symptoms, but active
. 50% of the time)
9 (4) 3 (4)
Race or ethnic group .65
White 67 (86) 62 (82)
Other race 10 (1) 12 (3)
Missing data 1 (13) 2 (16)
Tumor size, cm .24
# 2 39 (49) 30 (39)
. 2 to # 5 36 (45) 45 (55)
. 5 3 (6) 1 (6)
No. of positive lymph nodes
0 37 (47) 36 (47) .55
1-3 30 (38) 25 (33)
4-9 8 (10) 12 (16)
$ 10 1 (1) 0 (0)
Missing data 2 (3) 3 (1)
Tumor grade .28
Low 3 (4) 0 (0)
Intermediate 17 (22) 19 (25)
High 49 (63) 54 (71)
Missing data 9 (12) 3 (4)
Type of surgery .42
Lumpectomy and breast
irradiation
36 (47) 41 (54)
Mastectomy 42 (53) 35 (46)
(continued on following page)
TABLE A3. Kaplan-Meier Estimates for Patients with Triple-Negative Breast Cancer
Outcome Median (years; 95% CI) 5-Year Estimate (%; 95% CI) 10-Year Estimate (%; 95% CI)
RFS 8.9 (7.7 to 10.6) 65.1 (63.7 to 78.4) 42.2 (34.7 to 51.3)
OS 9.8 (8.8 to 11.3) 70.7 (78.6 to 84.7) 48.2 (40.5 to 57.4)
BCSS NA 80.4 (74.2 to 87.2) 78.4 (71.7 to 85.7)
Abbreviations: BCSS, breast cancer–specific survival; NA, not available; OS, overall survival; RFS, relapse-free survival.
TABLE A2. Characteristics of Patients With Triple-Negative Breast Cancer
(continued)
Characteristic








Sentinel node biopsy only 22 (28) 23 (30)
Axillary dissection only 29 (37) 25 (33)
Both sentinel node biopsy and
axillary dissection
26 (33) 27 (36)
Neither sentinel node biopsy
nor axillary dissection
1 (1) 1 (, 1)
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF,
cyclophosphamide, methotrexate, and fluorouracil.
TABLE A4. Multivariable Cox Proportional Hazards Models for Patients With Triple-Negative Breast Cancer (N = 154)
Variable
Relapse-Free Survival Overall Survival Breast Cancer–Specific Survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Treatment
Capecitabine 1 (Ref) .0296 1 (Ref) .1533 1 (Ref) .1564
CMF or AC 0.61 (0.39 to 0.95) 0.71 (0.45 to 1.14) 0.56 (0.25 to 1.25)
Age group, years
65-69 1 (Ref) .1693 1 (Ref) .0654 1 (Ref) .1338
$ 70 1.49 (0.84 to 2.63) 1.84 (0.96 to 3.54) 3.18 (0.70 to 14.41)
Race
White 1 (Ref) .9565 1 (Ref) .9290 1 (Ref) .7445
Other 1.02 (0.55 to 1.88) 1.03 (0.54 to 1.96) 0.82 (0.24 to 2.75)
Tumor size, cm
# 2 1 (Ref) .4112 1 (Ref) .2303 1 (Ref) .7334
. 2 1.20 (0.77 to 1.87) 1.33 (0.83 to 2.12) 1.15 (0.52 to 2.54)
No. of positive lymph nodes
0 1 (Ref) .0089 1 (Ref) , .001 1 (Ref) .0028
1-3 1.89 (1.17 to 3.06) 2.32 (1.38 to 3.88) 5.00 (1.62 to 15.44)
$ 4 2.30 (1.24 to 4.29) 3.16 (1.64 to 6.05) 8.03 (2.42 to 26.68)
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil; HR, hazard ratio; Ref,
reference.
